CAJ | 학술논문

目的：探讨左卡尼汀（Levocarnitine，LCN）静脉注射对腹膜透析患者肾性贫血（Renal anemia，RA）的临床疗效及安全性。方法选择我院肾内科2011年1月~2012年12月进行持续性非卧床腹膜透析治疗（CAPD）患者46例作为研究对象，采用随机数字表法分为静脉注射 LCN组和常规治疗组各23例，两组均按每周100~150 U/kg应用促红细胞生成素（EPO），分2～3次皮下注射，同时常规口服铁剂及叶酸，LCN组在上述治疗的基础上加用 LCN隔日1次静脉注射，疗程12w。结果治疗12w后LCN组血红蛋白（Hb）、红细胞压积（Hct）上升幅度明显高于B组（P＜0.05）；LCN组EPO用量显著少于对照组（P＜0.05）；LCN治疗组出现高血压2例，发生率为8.6％；常规治疗组为6例，发生率为26.1％；LCN组不良反应发生率显著低于常规治疗组(P<0.05)。结论常规治疗的基础上联合使用 LCN可显著提高CAPD患者Hb含量和HCT百分比，降低肾性贫血的发生风险，降低高血压等不良反应发生率。
목적：탐토좌잡니정（Levocarnitine，LCN）정맥주사대복막투석환자신성빈혈（Renal anemia，RA）적림상료효급안전성。방법선택아원신내과2011년1월~2012년12월진행지속성비와상복막투석치료（CAPD）환자46례작위연구대상，채용수궤수자표법분위정맥주사 LCN조화상규치료조각23례，량조균안매주100~150 U/kg응용촉홍세포생성소（EPO），분2～3차피하주사，동시상규구복철제급협산，LCN조재상술치료적기출상가용 LCN격일1차정맥주사，료정12w。결과치료12w후LCN조혈홍단백（Hb）、홍세포압적（Hct）상승폭도명현고우B조（P＜0.05）；LCN조EPO용량현저소우대조조（P＜0.05）；LCN치료조출현고혈압2례，발생솔위8.6％；상규치료조위6례，발생솔위26.1％；LCN조불량반응발생솔현저저우상규치료조(P<0.05)。결론상규치료적기출상연합사용 LCN가현저제고CAPD환자Hb함량화HCT백분비，강저신성빈혈적발생풍험，강저고혈압등불량반응발생솔。
Objective To evaluate the eficacy of L-carnitine in the treatment of peritoneal dialysis patients with renal anemia. Methods Forty-six patients with peritoneal dialysis were divided into the two groups:23 patients were treated with L-carnltine(Group A),another 23 patients with regular treatmeat(Group B).Both groups received recombinant human erythropoietin (EPO)120-150 U/kg,3 times per week,subcutaneous injection and at the same time the two groups were given oral iron supplements and folic acid.Group A was given L-carnitine 1 gram 3 times every week for 3 months. Results Haemoglobin(Hb)and haematocrit(Hct)in Group A were al significantly increased than those in Group B. Conclusion Treatment combination of L-carnitine may improve the ef icacy of renal anemia in peritoneal dialysis and reduce the dosage of EPO and adverse ef ect.